Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vespireit

ApprovedSmall molecule

VValenta Pharm JSC

Vespireit is one of 16 small molecule programs targeting Vertigo. It is currently in Approved.

1

Indications

1

Total Trials

1

Active Trials

15

Competitors

Pipeline

Status by Indication[3][1]

Indication

VertigoActive, not recruiting

VertigoApproved

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Vertigo

#DrugCompanyPhaseTrials

Reglan

IIstituto Clinico Humanitas

Valium

Akero Therapeutics

Buspar

Bristol-Myers Squibb

DLBS1033

DDexa Medica Group

Ginger

UUniversity of Rochester

Antivert

Alnylam Pharmaceuticals

Ativan

BBausch Health Americas, Inc.

Phenergan

BBassett Healthcare

Zovirax

BBp Consulting, Inc

Dimenhydrinate

SSt. Justine's Hospital

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Vertigo

NCT06321341

Clinical

Trials by Indication[1]

Vertigo1 trial

Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome Accompanied by Functional Vertigo

Recruiting·VValenta Pharm JSC·Phase 4·NCT06321341·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vespireit. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vespireit compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vespireit. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valenta Pharm JSC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: VValenta Pharm JSC

Related News